Table 4.
Clinicopathological features of MMRd–POLEmut ECs
| MMRd–POLEmut ECs | |
|---|---|
| n = 30 (100%) | |
| Age, years | |
| Mean [range] | 66.5 [27–87] |
| < 60 | 9 (30) |
| 60–70 | 8 (26.7) |
| > 70 | 13 (43.3) |
| Stage | |
| IA | 14 (46.6) |
| IB | 10 (33.3) |
| II | 3 (10) |
| III | 4 (10) |
| IV | 0 (0) |
| Histology | |
| Endometrioid | 25 (83.3) |
| Serous | 1 (3.3) |
| Mixed | 2 (6.7) |
| Clear cell | 3 (6.7) |
| Grade | |
| 1–2 | 19 (63.3) |
| 3 | 11 (36.7) |
| Myometrium invasion | |
| < 50% | 13 (43.3) |
| > 50% | 15 (56.7) |
| LVSI | |
| Absent | 21 (70) |
| Present | 4 (13.3) |
| Missing | 5 (16.7) |
| Treatment | |
| None | 7 (23.3) |
| Radiotherapy | 10 (33.3) |
| Chemotherapy | 1 (3.3) |
| Radiochemotherapy | 5 (16.7) |
| Unknown | 7 (23.3) |
| POLE mutations | |
| Pathogenic mutation | 14 (46.7) |
| Non‐pathogenic mutation/variant of unknown significance | 16 (53.3) |